Increasing drug experimentation in developing countries


Introduction of experimental pharmaceuticals into less developed countries where public health regulations are not restrictive, is an increasing phenomenon.


Trials of new contraceptive drugs, for example, are often conducted in Third World countries which may have no preclinical requirements or supervision for therapeutic testing; pharmaceutical companies may wish to evade controls imposed for the safety of women's health in such trials. Drug companies in the USA, for example, spend between 15 and 20% of their research budgets abroad, mainly in developing countries, for all kinds of products.

Related UN Sustainable Development Goals:
GOAL 3: Good Health and Well-beingGOAL 11: Sustainable Cities and Communities
Problem Type:
E: Emanations of other problems
Date of last update
04.10.2020 – 22:48 CEST